Core Viewpoint - Guojin Securities issued a report on August 22, giving a "buy" rating to Tiantan Biological (600161.SH, latest price: 20.39 yuan) based on several key factors [2] Group 1: Financial Performance - The revenue from albumin and intravenous immunoglobulin (IVIG) continues to grow, although the overall profit from blood products is under pressure [2] Group 2: Market Position - The number of single plasma collection stations and the scale of plasma collection remain the leading position in the domestic market [2] Group 3: Innovation and R&D - The company is committed to innovation-driven strategies, with research and development progress proceeding smoothly [2]